Efficacy News and Research

RSS

IOF review outlines pathophysiology, diagnosis and management of osteoporosis in young adults

Much of the research defining osteoporosis and fracture risk has focused on older adults, i.e. postmenopausal women and men over the age of 50. While older adults are at highest risk of osteoporosis and related fractures, the disease can also affect younger adults between 20 and 50 years of age. However, the diagnosis and management of osteoporosis in young adults is complicated by special challenges, including a complex pathophysiology and the related fact that there is no clear definition of osteoporosis, or of intervention thresholds, in this age group.

20 Jun 2012

Combination therapy may help defeat pancreatic cancer

Combining a new targeted therapy with standard chemotherapy may help defeat pancreatic cancer, according to results presented at the American Association for Cancer Research's Pancreatic Cancer: Progress and Challenges conference, held here June 18-21.

20 Jun 2012

Furiex initiates MuDelta Phase III studies in IBS-D

Furiex Pharmaceuticals, Inc. today announced dosing of the first patient in its Phase III randomized, double-blind, placebo-controlled studies evaluating efficacy, safety and tolerability of MuDelta (JNJ-27018966) in the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D).

20 Jun 2012

Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, announced that it is has successfully completed a Phase 1 single ascending dose (SAD) clinical study with Z944, its novel, oral, T-type calcium channel blocker.

19 Jun 2012

Sustained ventricular arrhythmias in NSTE ACS rare but high-risk

Sustained ventricular fibrillation or tachycardia in patients admitted with non-ST-segment elevation acute coronary syndrome are uncommon but worsen patients’ prognosis markedly if they do develop, researchers report.

19 Jun 2012

MAQUET's INTERGARD SYNERGY vascular graft receives CE mark

MAQUET Cardiovascular, LLC announced today that it has received CE mark for its INTERGARD SYNERGY vascular graft. This graft represents the next generation in antimicrobial grafts combining the well-known antimicrobial properties of silver acetate and triclosan.

19 Jun 2012

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

Today Abbott announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease.

19 Jun 2012

iBio expands iBioModulator portfolio with allowance of patent for anthrax vaccines

iBio, Inc. today announced that the US Patent Office has allowed patent application 11/706,576 entitled "Bacillus anthracis Antigens, Vaccine Compositions, and Related Methods."

19 Jun 2012

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Pfizer Inc. announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on its New Drug Application (NDA) for tafamidis meglumine.

19 Jun 2012

Mylan's new online resource seeks to dispel common misconceptions about generic drugs

Mylan Pharmaceuticals ULC, the Canadian subsidiary of Mylan Inc., announced today the introduction of a new online resource, ChoosingGenerics.ca, to help Canadians learn more about the value, reliability and quality of generic pharmaceuticals. The website is a public awareness tool that seeks to dispel common misconceptions and help Canadians learn more about the benefits of generic drugs.

18 Jun 2012

Henry Schein Medical to distribute Alma Lasers' nail fungus treatment

Alma Lasers, Inc. has announced an exclusive distribution arrangement with Henry Schein Medical to launch its latest innovation Harmony ClearChoice – a new, fast, effective approach to nail restoration.

18 Jun 2012

Novel strategy for neutralizing unwanted molecules and clearing them from the body

Researchers have unveiled a novel strategy for neutralizing unwanted molecules and clearing them from the body.

18 Jun 2012

Spectros introduces OnCall wireless remote access to view real-time patient results

Spectros Corporation announces the successful launch of OnCall wireless remote access for viewing real-time patient results on T-Stat white light tissue oximeters.

18 Jun 2012

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

DBV Technologies, creator of Viaskin, a new standard in the treatment of allergy, announced today that AP-HP (Assistance Public - Hôpitaux de Paris) sponsor of the ARACHILD study presented at the EAACI Congress a late breaking oral presentation on safety and efficacy data after six months of epicutaneous immunotherapy in peanut allergy using Viaskin Peanut.

18 Jun 2012

FDA completes review of compounded hydroxyprogesterone caproate products and APIs

FDA (or the Agency) approved Makena (hydroxyprogesterone caproate) in February 2011 for the reduction of the risk of certain preterm births in women who have had at least one prior preterm birth. Beginning many years before Makena was approved, a version of the active ingredient of Makena has been available to patients whose physicians requested the drug from a pharmacist who compounded the drug.

18 Jun 2012

UW initiates enrollment in tosedostat phase II combination study for AML, MDS

Cell Therapeutics, Inc. today announced that the University of Washington has begun enrolling patients in a randomized phase II study testing the combination of tosedostat with either cytarabine or decitabine for elderly patients with newly-diagnosed acute myeloid leukemia ("AML") or high-risk myelodysplastic syndrome.

18 Jun 2012

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Pharmacyclics, Inc announced today at the 17th Congress of European Hematology Association updated results from two clinical trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

18 Jun 2012

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

At the 17th Congress of the European Hematology Association in Amsterdam Professor Max Topp of the University of Wuerzberg in Germany presents the impressive results with a bispecific antibody for Acute Lymphoblastic Leukemia patients.

18 Jun 2012

Study reveals value of graphic warning labels on cigarette packaging

In a first of its kind study in the U.S., researchers at the Perelman School of Medicine at the University of Pennsylvania have shown that the addition of graphic warning labels on cigarette packaging can improve smokers' recall of the warning and health risks associated with smoking. The new findings are published online-first in the American Journal of Preventive Medicine.

16 Jun 2012

Efficacy News and Research

IOF review outlines pathophysiology, diagnosis and management of osteoporosis in young adults

Combination therapy may help defeat pancreatic cancer

Furiex initiates MuDelta Phase III studies in IBS-D

Positive results from Zalicus Z944 Phase 1 SAD clinical study for chronic inflammatory pain

Sustained ventricular arrhythmias in NSTE ACS rare but high-risk

MAQUET's INTERGARD SYNERGY vascular graft receives CE mark

Five abstracts evaluating Abbott's LCIG presented at Parkinson's disease congress

iBio expands iBioModulator portfolio with allowance of patent for anthrax vaccines

Pfizer receives FDA Complete Response Letter for tafamidis meglumine NDA

Mylan's new online resource seeks to dispel common misconceptions about generic drugs

Henry Schein Medical to distribute Alma Lasers' nail fungus treatment

Novel strategy for neutralizing unwanted molecules and clearing them from the body

Spectros introduces OnCall wireless remote access to view real-time patient results

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

DBV Technologies’ Viaskin safe and effective in treating children with peanut allergy

FDA completes review of compounded hydroxyprogesterone caproate products and APIs

UW initiates enrollment in tosedostat phase II combination study for AML, MDS

Updated results from two clinical trials of Bruton's ibrutinib for CLL/SLL

Impressive results from blinatumomab Phase 2 study on B-precursor ALL

Study reveals value of graphic warning labels on cigarette packaging

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News